82317-83-7

Basic information

• Product Name: BOC-D-4-Trifluoromethylphe
• Synonyms: Boc-p-trifluoromethyl-D-phenylalanine;Boc-D-Phe(4-CF3)-OH;Boc-π-trifluoromethyl-D-phenylalanine≥ 98%;BOC-D-PHE(P-CF3)-OH;BOC-D-PHE(4-CF3)-OH;BOC-D-PHE(4-TRIFLUOROMETHYL)-OH;BOC-4-(TRIFLUOROMETHYL)-D-PHENYLALANINE;BOC-D-4-TRIFLUOROMETHYLPHE
• CAS NO: 82317-83-7
• Molecular Formula: C₁₅H₁₈F₃NO₄
• Molecular Weight: 333.3
• Product Categories: Amino Acids;Phenylalanine analogs and other aromatic alpha amino acids;a-amino
• Mol File: 82317-83-7.mol
• Article Data: 6

Chemical Properties

• Melting Point: 135-140°C
• Boiling Point: 431.4 °C at 760 mmHg
• Flash Point: 214.7 °C
• Appearance: /
• Density: 1.271 g/cm³
• Storage Temp.: Keep Cold
• PKA: 3.76±0.10(Predicted)
• CAS DataBase Reference: BOC-D-4-Trifluoromethylphe(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-D-4-Trifluoromethylphe(82317-83-7)
• EPA Substance Registry System: BOC-D-4-Trifluoromethylphe(82317-83-7)

Safety Data

• Hazard Codes: Xi
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 82317-83-7(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Upstream product

• 176795-01-0 C₁₆H₂₀F₃NO₄ 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3832-75-5 (S)-4-trifluoromethylphenylalanine 
• 402-49-3 4-bromomethyltrifluoromethylbenzene 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 82317-77-9 methyl (R)-2-acetamido-3-(4-(trifluoromethyl)phenyl)propanoate 
• 82317-73-5 2-Acetylamino-3-(4-trifluoromethyl-phenyl)-propionic acid methyl ester 
• 114872-59-2 diethyl 2-acetamido-2-<<4-(trifluoromethyl)phenyl>methyl>malonate 
• 82337-58-4 2-acetamido-3-(4-(trifluoromethyl)phenyl)propanoic acid 
• 3832-77-7 (R)-2-Amino-3-(4-trifluoromethyl-phenyl)-propionic acid; hydrochloride 

Downstream Products

• 119744-87-5 [(S)-1-Carbamoyl-2-(4-trifluoromethyl-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 125218-25-9 (S)-2-[(S)-2-(2-{2-[(S)-2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-acetylamino}-acetylamino)-3-(4-trifluoromethyl-phenyl)-propionylamino]-4-methyl-pentanoic acid; hydrochloride 
• 1435265-88-5 N-(N-benzoyl-L-tryptophanyl)-para-trifluoromethyl-D-phenylalanine methyl ester 
• 444583-33-9 4-trifluoromethyl-d-phenylalanine methyl ester 
• 1416468-71-7 tert-butyl {(2R)-1-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl]piperidin-1-yl}-1-oxo-3-[4-(trifluoromethyl)phenyl]propan-2-yl}carbamate 
• 1416467-53-2 4-[5-(cyclopropylmethoxy)-1,3-benzodioxol-4-yl]-N-{(2R)-1-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl]piperidin-1-yl}-1-oxo-3-[4-(trifluoromethyl)phenyl]propan-2-yl}-5H-pyrrolo[3,2-d]pyrimidine-7-carboxamide 
• 1416468-49-9 (4aS,8aR)-2-(1-{(2R)-2-amino-3-[4-(trifluoromethyl)phenyl]propanoyl}piperidin-4-yl)-4-(3,4-dimethoxyphenyl)-4a,5,6,7,8,8a-hexahydrophthalazin-1(2H)-one 
• 1378243-29-8 C₂₃H₃₂F₃N₃O₅S 
• 1378243-19-6 C₂₇H₄₀F₃N₃O₆S 

Relevant articles and documents

Structure–Activity Relationship Studies on (R)-PFI-2 Analogues as Inhibitors of Histone Lysine Methyltransferase SETD7

SETD7 is a histone H3K4 lysine methyltransferase involved in human gene regulation. Aberrant expression of SETD7 has been associated with various diseases, including cancer. Therefore, SETD7 is considered a good target for the development of new epigenetic drugs. To date, few selective small-molecule inhibitors have been reported that target SETD7, the most potent being (R)-PFI-2. Herein we report structure–activity relationship studies on (R)-PFI-2 and its analogues. A library of 29 structural analogues of (R)-PFI-2 was synthesized and evaluated for inhibition of recombinantly expressed human SETD7. The key interactions were found to be a salt bridge and a hydrogen bond formed between (R)-PFI-2′s NH2+ group and SETD7′s Asp256 and His252 residue, respectively.

N-acylamino acid amide compounds and intermediates for preparation thereof

The present invention discloses the compound represented by the formula (I): wherein A represents the following formula (a-1) or the following formula (a-2): B represents the following formula (b): (wherein the symbols are each as defined in the specification) or a pharmaceutically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.

Amino acids and peptides. X. Leu-enkephalin analogues containing a fluorinated aromatic amino acid

-